Rezolute is a clinical-stage biopharmaceutical company developing ersodetug, an intravenously administered monoclonal antibody designed to treat severe hypoglycemia caused by hyperinsulinism (HI), a rare condition in which the pancreas produces excessive insulin. The company's lead program targets congenital hyperinsulinism, the most common cause of persistent hypoglycemia in infants and young children, as well as tumor-related hyperinsulinism caused by insulinomas and other insulin-secreting tumors; combined, these markets represent approximately 3,000 patients in the United States with limited treatment options. Rezolute generates value by advancing ersodetug through late-stage clinical trials, holding exclusive worldwide rights to the underlying patents, and seeking regulatory approval and commercialization of the therapy, with potential revenue generation through future product sales to patients, hospitals, and healthcare systems treating these rare hypoglycemic disorders.